Daniel Lozano

List of Publications by Year
in descending order

52 papers	2,788 citations	147801 31 h-index	182427 51 g-index
55 all docs	55 docs citations	55 times ranked	4051 citing authors

#	Article	IF	Citations
1	Engineering mesoporous silica nanoparticles for drug delivery: where are we after two decades?. Chemical Society Reviews, 2022, 51, 5365-5451.	38.1	138
2	Designing Mesoporous Silica Nanoparticles to Overcome Biological Barriers by Incorporating Targeting and Endosomal Escape. ACS Applied Materials & Interfaces, 2021, 13, 9656-9666.	8.0	39
3	Osteoporosis Remission and New Bone Formation with Mesoporous Silica Nanoparticles. Advanced Science, 2021, 8, e2101107.	11.2	53
4	Nanoantibiotics Based in Mesoporous Silica Nanoparticles: New Formulations for Bacterial Infection Treatment. Pharmaceutics, 2021, 13, 2033.	4.5	11
5	The effect of biomimetic mineralization of 3D-printed mesoporous bioglass scaffolds on physical properties and in vitro osteogenicity. Materials Science and Engineering C, 2020, 109, 110572.	7.3	19
6	Mesoporous Silica Nanoparticles for Targeting Subcellular Organelles. International Journal of Molecular Sciences, 2020, 21, 9696.	4.1	32
7	ZnO-mesoporous glass scaffolds loaded with osteostatin and mesenchymal cells improve bone healing in a rabbit bone defect. Journal of Materials Science: Materials in Medicine, 2020, 31, 100.	3.6	14
8	Mesoporous Silica Nanoparticles as Carriers for Therapeutic Biomolecules. Pharmaceutics, 2020, 12, 432.	4.5	68
9	Engineered pH-Responsive Mesoporous Carbon Nanoparticles for Drug Delivery. ACS Applied Materials & Interfaces, 2020, 12, 14946-14957.	8.0	59
10	Biomaterials against Bone Infection. Advanced Healthcare Materials, 2020, 9, e2000310.	7.6	75
11	Nanoparticles to Knockdown Osteoporosis-Related Gene and Promote Osteogenic Marker Expression for Osteoporosis Treatment. ACS Nano, 2019, 13, 5451-5464.	14.6	101
12	Advances in mesoporous silica nanoparticles for targeted stimuli-responsive drug delivery: an update. Expert Opinion on Drug Delivery, 2019, 16, 415-439.	5.0	124
13	Osteostatin potentiates the bioactivity of mesoporous glass scaffolds containing Zn2+ ions in human mesenchymal stem cells. Acta Biomaterialia, 2019, 89, 359-371.	8.3	42
14	Parathyroid hormone-related protein exhibits antioxidant features in osteoblastic cells through its N-terminal and osteostatin domains. Bone and Joint Research, 2018, 7, 58-68.	3.6	23
15	Lectin-conjugated pH-responsive mesoporous silica nanoparticles for targeted bone cancer treatment. Acta Biomaterialia, 2018, 65, 393-404.	8.3	161
16	Building Block Based Construction of Membrane-Organelle Double Targeted Nanosystem for Two-Drug Delivery. Bioconjugate Chemistry, 2018, 29, 3677-3685.	3.6	12
17	Features of aminopropyl modified mesoporous silica nanoparticles. Implications on the active targeting capability. Materials Chemistry and Physics, 2018, 220, 260-269.	4.0	9
18	Osteogenic Effect of ZnO-Mesoporous Glasses Loaded with Osteostatin. Nanomaterials, 2018, 8, 592.	4.1	29

#	Article	IF	Citations
19	Evaluation of bacterial adherence of clinical isolates of Staphylococcus sp. using a competitive model. Bone and Joint Research, 2017, 6, 315-322.	3.6	22
20	Self-immolative polymers as novel pH-responsive gate keepers for drug delivery. RSC Advances, 2017, 7, 132-136.	3.6	50
21	A novel visible light responsive nanosystem for cancer treatment. Nanoscale, 2017, 9, 15967-15973.	5.6	72
22	Janus Mesoporous Silica Nanoparticles for Dual Targeting of Tumor Cells and Mitochondria. ACS Applied Materials & Interfaces, 2017, 9, 26697-26706.	8.0	93
23	Local delivery of parathyroid hormone-related protein-derived peptides coated onto a hydroxyapatite-based implant enhances bone regeneration in old and diabetic rats. Journal of Biomedical Materials Research - Part A, 2016, 104, 2060-2070.	4.0	25
24	Selective topotecan delivery to cancer cells by targeted pH-sensitive mesoporous silica nanoparticles. RSC Advances, 2016, 6, 50923-50932.	3.6	46
25	Adverse Effects of Diabetes Mellitus on the Skeleton of Aging Mice. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2016, 71, 290-299.	3.6	10
26	Fabrication of novel Si-doped hydroxyapatite/gelatine scaffolds by rapid prototyping for drug delivery and bone regeneration. Acta Biomaterialia, 2015, 15, 200-209.	8.3	164
27	Bone fracture healing: Cell therapy in delayed unions and nonunions. Bone, 2015, 70, 93-101.	2.9	330
28	Osteostatin-Coated Porous Titanium Can Improve Early Bone Regeneration of Cortical Bone Defects in Rats. Tissue Engineering - Part A, 2015, 21, 1495-1506.	3.1	32
29	Influence of the nanostructure of <scp>F</scp>â€doped TiO₂ films on osteoblast growth and function. Journal of Biomedical Materials Research - Part A, 2015, 103, 1985-1990.	4.0	27
30	Functional Roles of the Nuclear Localization Signal of Parathyroid Hormone-Related Protein (PTHrP) in Osteoblastic Cells. Molecular Endocrinology, 2014, 28, 925-934.	3.7	23
31	Parathyroid hormone-related protein (107-111) improves the bone regeneration potential of gelatinâ€“glutaraldehyde biopolymer-coated hydroxyapatite. Acta Biomaterialia, 2014, 10, 3307-3316.	8.3	28
32	Characterization of Hybrid Bioactive Glass-polyvinyl Alcohol Scaffolds Containing a PTHrP-derived Pentapeptide as Implants for Tissue Engineering Applications. Open Biomedical Engineering Journal, 2014, 8, 20-27.	0.5	10
33	Treatment with N- and C-Terminal Peptides of Parathyroid Hormone-Related Protein Partly Compensate the Skeletal Abnormalities in IGF-I Deficient Mice. PLoS ONE, 2014, 9, e87536.	2.5	20
34	ComparaciÃ³n de las acciones osteogÃ©nicas de la proteÃna relacionada con la parathormona (PTHrP) en modelos de ratÃ³n diabÃ©tico y con dÃ©ficit del factor de crecimiento similar a la insulina tipo I (IGF-I). Revista De Osteoporosis Y Metabolismo Mineral, 2014, 6, 46-56.	0.3	0
35	Characterization of skeletal alterations in a model of prematurely aging mice. Age, 2013, 35, 383-393.	3.0	7
36	Inhibition of the canonical Wnt pathway by high glucose can be reversed by parathyroid hormoneâ€related protein in osteoblastic cells. Journal of Cellular Biochemistry, 2013, 114, 1908-1916.	2.6	35

#	Article	IF	Citations
37	Amylin exerts osteogenic actions with different efficacy depending on the diabetic status. Molecular and Cellular Endocrinology, 2013, 365, 309-315.	3.2	14
38	The vertebrae of prematurely aging mice as a skeletal model of involutional osteoporosis. Histology and Histopathology, 2013, 28, 1473-81.	0.7	0
39	Osteostatin improves the osteogenic activity of fibroblast growth factor-2 immobilized in Si-doped hydroxyapatite in osteoblastic cells. Acta Biomaterialia, 2012, 8, 2770-2777.	8.3	40
40	Osteostatin-loaded onto mesoporous ceramics improves the early phase of bone regeneration in a rabbit osteopenia model. Acta Biomaterialia, 2012, 8, 2317-2323.	8.3	51
41	Comparison of the skeletal effects induced by daily administration of PTHrP (1â€“36) and PTHrP (107â€“139) to ovariectomized mice. Journal of Cellular Physiology, 2012, 227, 1752-1760.	4.1	56
42	Role of angiogenesis on bone formation. Histology and Histopathology, 2012, 27, 559-66.	0.7	95
43	The Câ€terminal fragment of parathyroid hormoneâ€related peptide promotes bone formation in diabetic mice with lowâ€turnover osteopaenia. British Journal of Pharmacology, 2011, 162, 1424-1438.	5.4	43
44	Comparison of the osteoblastic activity conferred on Si-doped hydroxyapatite scaffolds by different osteostatin coatings. Acta Biomaterialia, 2011, 7, 3555-3562.	8.3	43
45	Immobilization and bioactivity evaluation of FGF-1 and FGF-2 on powdered silicon-doped hydroxyapatite and their scaffolds for bone tissue engineering. Journal of Materials Science: Materials in Medicine, 2011, 22, 405-416.	3.6	32
46	GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia. Journal of Endocrinology, 2011, 209, 203-210.	2.6	76
47	The osteoinductive properties of mesoporous silicate coated with osteostatin in a rabbit femur cavity defect model. Biomaterials, 2010, 31, 8564-8573.	11.4	87
48	Alterations of the Wnt/Î²â€catenin pathway and its target genes for the Nâ€and Câ€terminal domains of parathyroid hormoneâ€related protein in bone from diabetic mice. FEBS Letters, 2010, 584, 3095-3100.	2.8	60
49	Osteostatin-loaded bioceramics stimulate osteoblastic growth and differentiation. Acta Biomaterialia, 2010, 6, 797-803.	8.3	85
50	Role of the N- and C-terminal Fragments of Parathyroid-Hormone-Related Protein as Putative Therapies to Improve Bone Regeneration Under High Glucocorticoid Treatment. Tissue Engineering - Part A, 2010, 16, 1157-1168.	3.1	31
51	Role of Parathyroid Hormone-Related Protein in the Decreased Osteoblast Function in Diabetes-Related Osteopenia. Endocrinology, 2009, 150, 2027-2035.	2.8	68
52	Diabetes mellitus y pÃ©rdida de masa Ã³sea. Revista EspaÃ±ola De Enfermedades MetabÃ³licas Ã“seas, 2007, 16, 29-33.	0.0	0